A carregar...
Targeting EGFR and ALK in NSCLC: current evidence and future perspective
The advent of molecular therapy targeting specific driver oncogenes has dramatically changed the prognosis of a subset of NSCLC, dilating survival and improving the quality of life of patients with advanced disease. Two of the major targets for treatment with receptor TKIs are the activated mutated...
Na minha lista:
| Publicado no: | Lung Cancer Manag |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Future Medicine Ltd
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6310340/ https://ncbi.nlm.nih.gov/pubmed/30643552 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/lmt-2016-0005 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|